D. E. Shaw & Co. Inc. Buys 155,086 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

D. E. Shaw & Co. Inc. increased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 16.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,110,501 shares of the company’s stock after buying an additional 155,086 shares during the period. D. E. Shaw & Co. Inc. owned about 0.54% of Cellebrite DI worth $24,464,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of CLBT. NewEdge Advisors LLC raised its position in Cellebrite DI by 600.7% during the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock worth $86,000 after buying an additional 3,352 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Cellebrite DI in the fourth quarter valued at approximately $100,000. Polen Capital Management LLC acquired a new position in shares of Cellebrite DI during the 4th quarter valued at about $222,000. Victory Capital Management Inc. acquired a new stake in shares of Cellebrite DI during the 4th quarter worth approximately $234,000. Finally, HighTower Advisors LLC purchased a new stake in Cellebrite DI in the 4th quarter valued at about $274,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Lake Street Capital lifted their price objective on Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. boosted their price target on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $23.43.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $19.83 on Monday. The stock’s 50 day simple moving average is $18.92 and its 200 day simple moving average is $20.25. The company has a market capitalization of $4.75 billion, a price-to-earnings ratio of -14.27, a PEG ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a twelve month low of $10.25 and a twelve month high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, analysts forecast that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.